CD200R1 and arthritic joint disease: Fourth, we used IL-23OE in the arthritis-susceptible BALB/c inbred strain and intervened every 5 days with an agonistic anti-CD200R1 treatment (OX-110) starting on day 7 to restore the suppression of skin-derived precursors by resident CD200+ fibroblasts.